HK1205139A1 - Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage - Google Patents

Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage

Info

Publication number
HK1205139A1
HK1205139A1 HK15105619.3A HK15105619A HK1205139A1 HK 1205139 A1 HK1205139 A1 HK 1205139A1 HK 15105619 A HK15105619 A HK 15105619A HK 1205139 A1 HK1205139 A1 HK 1205139A1
Authority
HK
Hong Kong
Prior art keywords
repair
tissue damage
cell derived
stromal cell
derived factor
Prior art date
Application number
HK15105619.3A
Other languages
English (en)
Chinese (zh)
Inventor
Richard Lee
Vincent Segers
Original Assignee
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital Inc filed Critical Brigham & Womens Hospital Inc
Publication of HK1205139A1 publication Critical patent/HK1205139A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
HK15105619.3A 2006-10-23 2015-06-15 Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage HK1205139A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85344106P 2006-10-23 2006-10-23
US92935307P 2007-06-22 2007-06-22
US11/976,032 US7696309B2 (en) 2006-10-23 2007-10-19 Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage

Publications (1)

Publication Number Publication Date
HK1205139A1 true HK1205139A1 (en) 2015-12-11

Family

ID=39318162

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10103057.2A HK1136211A1 (en) 2006-10-23 2010-03-23 Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
HK15105619.3A HK1205139A1 (en) 2006-10-23 2015-06-15 Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK10103057.2A HK1136211A1 (en) 2006-10-23 2010-03-23 Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage

Country Status (10)

Country Link
US (6) US7696309B2 (xx)
EP (2) EP2094288A4 (xx)
JP (2) JP5695318B2 (xx)
CN (2) CN104211800B (xx)
AU (1) AU2007309479A1 (xx)
CA (1) CA2667280C (xx)
HK (2) HK1136211A1 (xx)
IL (2) IL198021A (xx)
NZ (1) NZ576188A (xx)
WO (1) WO2008051505A2 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260258A1 (en) 2003-12-18 2005-11-24 The Texas A&M University System Use of vitelline protein B as a microencapsulating additive
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
WO2010101628A2 (en) * 2009-03-02 2010-09-10 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
US9308277B2 (en) * 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US8741833B2 (en) * 2010-07-16 2014-06-03 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
WO2012027170A1 (en) * 2010-08-23 2012-03-01 Provasculon, Inc. Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
WO2012125808A1 (en) * 2011-03-15 2012-09-20 Massachusetts Institute Of Technology Multiplexed detection with isotope-coded reporters
CA2838155C (en) 2011-06-07 2021-10-19 Provasculon, Inc. Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
CN103740662B (zh) * 2012-05-10 2015-08-19 江南大学 一种提高酶热稳定性的方法
EP3004374B1 (en) 2013-06-07 2020-08-12 Massachusetts Institute of Technology Affinity-based detection of ligand-encoded synthetic biomarkers
CA2933620A1 (en) * 2013-12-13 2015-06-18 Mesoblast International Sarl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
CN104650192B (zh) * 2015-03-26 2017-06-23 罗忠礼 一类能用于修复子宫和保护心肌的自组装短肽及其应用
WO2017177115A1 (en) 2016-04-08 2017-10-12 Massachusetts Institute Of Technology Methods to specifically profile protease activity at lymph nodes
US11428689B2 (en) 2016-05-05 2022-08-30 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
AU2018248327A1 (en) 2017-04-07 2019-10-17 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
WO2019173332A1 (en) 2018-03-05 2019-09-12 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
CN109321481B (zh) * 2018-11-22 2020-12-29 湖南汇升生物科技有限公司 一种生麦芽糖淀粉酶生产菌株
CN109486792B (zh) * 2018-11-22 2019-12-10 湖南汇升生物科技有限公司 一种生麦芽糖淀粉酶突变体的制备及其应用
CN109439641B (zh) * 2018-11-22 2020-12-29 湖南汇升生物科技有限公司 一种生麦芽糖淀粉酶生产菌株的应用
CN109234339B (zh) * 2018-11-22 2020-12-29 湖南汇升生物科技有限公司 一种高纯度结晶麦芽糖的生产方法
EP3892330A4 (en) * 2018-12-04 2022-10-26 Chugai Seiyaku Kabushiki Kaisha CXCR3 LIGAND
US11835522B2 (en) 2019-01-17 2023-12-05 Massachusetts Institute Of Technology Sensors for detecting and imaging of cancer metastasis

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2081618T5 (es) * 1991-11-13 2005-09-01 T.A.C. Thrombosis And Coagulation Aktiebolag Metodo para diagnosticar anomalias de la coagulacion de la sangre.
US5670483A (en) 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
JP3367581B2 (ja) 1993-10-14 2003-01-14 小野薬品工業株式会社 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞
JP3329109B2 (ja) * 1994-12-02 2002-09-30 ソニー株式会社 プラズマアドレス表示装置
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6214540B1 (en) * 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
ATE258444T1 (de) 1998-03-13 2004-02-15 Univ British Columbia Therapeutische chemokine rezeptor antagonisten
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US20020107195A1 (en) 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
US6221856B1 (en) * 1999-02-03 2001-04-24 Inologic, Inc. Inositol derivatives for inhibiting superoxide anion production
US20050059584A1 (en) * 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
CA2335109A1 (en) 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
DE10027383A1 (de) 2000-06-02 2001-12-20 Rhein Biotech Proz & Prod Gmbh Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz
WO2001094420A1 (en) * 2000-06-05 2001-12-13 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
AU2002235168A1 (en) 2000-11-05 2002-05-15 University Of Florida Targeting pluripotent stem cells to tissues
AU2002220262A1 (en) 2000-11-09 2002-05-21 Genetics Institute, Llc Sdf-1 beta expressing tumor cells as tumor vaccines
US20020111290A1 (en) * 2000-12-01 2002-08-15 Bernhard Homey Uses of mammalian genes and related reagents
WO2002045717A1 (en) * 2000-12-06 2002-06-13 Tularik Inc. Lometrexol combination therapy
AU2002348241A1 (en) * 2001-11-24 2003-06-10 Image Analysis, Inc. Automatic detection and quantification of coronary and aortic calcium
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US7485141B2 (en) * 2002-05-10 2009-02-03 Cordis Corporation Method of placing a tubular membrane on a structural frame
WO2003094950A2 (en) 2002-05-10 2003-11-20 Ipf Pharmaceuticals Gmbh A method of inhibiting the emigration of cells from the intravascular compartment into tissues
CN100366257C (zh) * 2002-08-22 2008-02-06 克里夫兰诊所基金会 基质细胞衍生因子-1介导缺血性心肌病中干细胞归巢及组织再生
US20050271639A1 (en) 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US20040037811A1 (en) 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
AU2003259991A1 (en) * 2002-08-23 2004-03-11 Bristol-Myers Squibb Company Methods of reducing ischemic injury
US20070060512A1 (en) 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
WO2004094465A2 (en) 2003-04-23 2004-11-04 The Board Of Trustees Of The University Of Illinois Office Of Technology Management University Of Illinois At Urbana-Champaign Synthetic molecules that mimic chemokines
CN1252089C (zh) * 2003-09-16 2006-04-19 广州润兴生物科技有限公司 基质细胞衍生因子－1α重组突变体的构建和制备
WO2006124013A2 (en) 2004-04-30 2006-11-23 Five Prime Therapeutics, Inc. Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use
CA2584553A1 (en) * 2004-09-17 2006-03-23 Cellgentech, Inc. External agent for treatment of skin ulcer
ES2645012T3 (es) * 2004-09-24 2017-12-01 Mesoblast, Inc. Método para potenciar la proliferación y/o supervivencia de las células precursoras mesenquimales (MPC)
US7399831B2 (en) 2004-10-25 2008-07-15 The Brigham And Women's Hospital, Inc. Targeted delivery of biological factors using self-assembling peptide nanofibers
US20060110374A1 (en) * 2004-11-24 2006-05-25 Dudy Czeiger Method to accelerate stem cell recruitment and homing
JP2008526749A (ja) 2005-01-04 2008-07-24 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド 自己アセンブリするペプチドナノファイバーを用いたｐｄｇｆの徐放性の送達
US8153592B2 (en) 2005-01-10 2012-04-10 Mayo Foundation For Medical Education And Research Modulating toll-like receptor activity
KR20100102750A (ko) * 2005-04-25 2010-09-24 메사추세츠 인스티튜트 오브 테크놀로지 지혈 및 다른 생리학적 활성을 촉진하기 위한 조성물 및 방법
UA96926C2 (ru) 2005-10-31 2011-12-26 Мерк Сероно Са Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
WO2007079460A2 (en) 2006-01-04 2007-07-12 Chemokine Therapeutics Corporation Design of cxc chemokine analogs for the treatment of human diseases
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US20080194478A1 (en) * 2007-02-09 2008-08-14 Gene Signal International Sa Wound healing agent and composition
JPWO2010024300A1 (ja) * 2008-08-26 2012-01-26 国立大学法人北海道大学 骨充填型軟骨組織再生誘導剤
CA2763156A1 (en) * 2009-05-20 2010-11-25 Board Of Regents, The University Of Texas System Identification of micro-rnas involved in post-myocardial infarction remodeling and heart failure

Also Published As

Publication number Publication date
US20220009984A9 (en) 2022-01-13
CN101553243B (zh) 2014-08-27
CA2667280C (en) 2015-12-01
EP2676674A1 (en) 2013-12-25
US20100184950A1 (en) 2010-07-22
JP2010507391A (ja) 2010-03-11
CA2667280A1 (en) 2008-05-02
US9631005B2 (en) 2017-04-25
HK1136211A1 (en) 2010-06-25
IL231752A0 (en) 2014-05-28
WO2008051505A8 (en) 2008-10-02
AU2007309479A1 (en) 2008-05-02
US20140024595A1 (en) 2014-01-23
EP2094288A2 (en) 2009-09-02
CN104211800B (zh) 2019-02-01
EP2676674B1 (en) 2017-06-21
NZ576188A (en) 2012-10-26
US20110269685A1 (en) 2011-11-03
JP5695318B2 (ja) 2015-04-01
IL198021A0 (en) 2011-08-01
CN104211800A (zh) 2014-12-17
IL198021A (en) 2014-11-30
US20210246182A1 (en) 2021-08-12
US20170101451A1 (en) 2017-04-13
US20080095758A1 (en) 2008-04-24
US10774124B2 (en) 2020-09-15
AU2007309479A2 (en) 2009-05-14
WO2008051505A2 (en) 2008-05-02
WO2008051505A3 (en) 2008-11-27
JP2015057058A (ja) 2015-03-26
CN101553243A (zh) 2009-10-07
US7999067B2 (en) 2011-08-16
EP2094288A4 (en) 2010-09-08
US7696309B2 (en) 2010-04-13

Similar Documents

Publication Publication Date Title
HK1205139A1 (en) Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
HK1225753A1 (zh) 使用胎盤幹細胞的免疫調節
GB2424118B (en) Fuel cells
EP2029049A4 (en) METHOD AND COMPOSITIONS FOR TISSUE REPAIR
GB2440434B (en) Fuel cells
GB0605878D0 (en) Fuel cells
EP2038379A4 (en) BIODIESEL GREEN
GB0614337D0 (en) Fuel Cells
IL195826A0 (en) Placental niche and use thereof to culture stem cells
HK1134835A1 (en) Methods for increasing and mobilizing hematopoietic stem cells
IL196913A0 (en) Suppressor trna transcription in vertebrate cells
GB2426452B (en) Tissue repair
EP1968418A4 (en) REPAIR OF NON-WEIGHT PARTS
GB0610414D0 (en) Tissue repair
EP1863113A4 (en) FUEL CELL
ZA200805081B (en) In vivo cell surface engineering
GB0606671D0 (en) Cell Culture
EP1865568A4 (en) FUEL CELL
ZA200803930B (en) Immunomodulation using placental stem cells
EP1941890A4 (en) PROLIFERATOR OF HEMATOPOIETIC STEM CELLS
EP1848052A4 (en) FUEL CELL
AU2006906146A0 (en) Stem cell tissue repair
GB0602208D0 (en) Embryonic stem cells
AU2006900110A0 (en) Human embryonic stem cell line
AU313292S (en) Vacuum cleaner